Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Bone Health in Men with Prostate Cancer: Review Article.

A M El Badri S, Salawu A, Brown JE.

Curr Osteoporos Rep. 2019 Dec;17(6):527-537. doi: 10.1007/s11914-019-00536-8. Review.

2.

Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.

Brufsky AM.

Oncologist. 2008 Feb;13(2):187-95. doi: 10.1634/theoncologist.2007-0152. Review.

3.

[Prostate cancer and Cancer Treatment-Induced Bone Loss(CTIBL)].

Matsushima H.

Clin Calcium. 2016 Jul;26(7):1039-45. doi: CliCa160710391045. Japanese.

PMID:
27346316
4.

Cancer-treatment-induced bone loss, part 2.

Michaud LB, Goodin S.

Am J Health Syst Pharm. 2006 Mar 15;63(6):534-46. Review.

PMID:
16522890
5.

Cancer treatment-induced bone loss in patients with breast or prostate cancer.

Maxwell C, Viale PH.

Oncol Nurs Forum. 2005 May 10;32(3):589-603. Review.

PMID:
15897934
6.

Cancer treatment-induced bone loss in breast and prostate cancer.

Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI.

J Clin Oncol. 2008 Nov 20;26(33):5465-76. doi: 10.1200/JCO.2008.18.4184. Epub 2008 Oct 27. Review.

PMID:
18955443
7.

Bone health in men receiving androgen deprivation therapy for prostate cancer.

Eastham JA.

J Urol. 2007 Jan;177(1):17-24. Review.

PMID:
17161994
8.

[ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].

Takahashi S.

Clin Calcium. 2011 Aug;21(8):1239-47. doi: CliCa110812391247. Review. Japanese.

PMID:
21814031
9.

Emerging drugs for the management of cancer treatment induced bone loss.

Bertoldo F, Pancheri S, Zenari S, Boldini S.

Expert Opin Emerg Drugs. 2010 Jun;15(2):323-42. doi: 10.1517/14728211003631385. Review.

PMID:
20377485
10.

Impact of denosumab on bone mass in cancer patients.

Brown-Glaberman U, Stopeck AT.

Clin Pharmacol. 2013 Jul 4;5:117-29. doi: 10.2147/CPAA.S30330. Print 2013.

11.

Cancer-treatment-induced bone loss, part 1.

Michaud LB, Goodin S.

Am J Health Syst Pharm. 2006 Mar 1;63(5):419-30. Review.

PMID:
16484516
12.

Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.

Israeli RS, Ryan CW, Jung LL.

J Urol. 2008 Feb;179(2):414-23. Review.

PMID:
18076933
13.

Practical guide to bone health in the spectrum of advanced prostate cancer.

Butoescu V, Tombal B.

Can J Urol. 2014 Apr;21(2 Supp 1):84-92. Review.

14.

Background to and management of treatment-related bone loss in prostate cancer.

Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa RM, Angeli A, Dogliotti L.

Drugs Aging. 2002;19(12):899-910. Review.

PMID:
12495366
15.

A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy.

Lee CE, Leslie WD, Czaykowski P, Gingerich J, Geirnaert M, Lau YK.

Curr Oncol. 2011 Aug;18(4):e163-72.

16.

Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer.

Michaud LB.

Am J Health Syst Pharm. 2010 Apr;67(7 Suppl 3):S20-30; quiz S31-3. doi: 10.2146/ajhp100078.

PMID:
20332495
17.

Antiresorptive therapy in the management of cancer treatment-induced bone loss.

Garg A, Leitzel K, Ali S, Lipton A.

Curr Osteoporos Rep. 2015 Apr;13(2):73-7. doi: 10.1007/s11914-014-0252-x. Review.

PMID:
25575469
18.

Prevention and treatment of bone loss in patients with nonmetastatic breast or prostate cancer who receive hormonal ablation therapy.

Limburg C, Maxwell C, Mautner B.

Clin J Oncol Nurs. 2014 Apr;18(2):223-30. doi: 10.1188/14.CJON.223-230.

PMID:
24675258
19.

A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.

Mohamad NV, Soelaiman IN, Chin KY.

Endocr Metab Immune Disord Drug Targets. 2017 Nov 16;17(4):276-284. doi: 10.2174/1871530317666170919112757. Review.

PMID:
28925899
20.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502

Supplemental Content

Support Center